glp-1 therapy in memphis tn Weight Loss Clinic | ZüpMed GLP-1 medications are changing more

Recent GLP-1 Weight Loss Drug Market Developments: Novo Nordisk, Eli Lilly, Amgen, and FDA Lead 20252026 April 2026: Eli Lilly submitted the orforglipron New Drug Application to the FDA for obesity treatment, reporting 14.7% body weight reduction in the ATTAIN-WEIGHT1 Phase 3 trial at the 45mg dose the first oral small molecule GLP-1 receptor agonist NDA submission for dedicated obesity pharmacological treatment in the United States

Am J Physiol Regul Integr Comp Physiol 2009;296:R67R71

Uncommon (110 in 1,000 people): diarrhea, vivid dreams, temporary increase in heart rate

We can coordinate care across visits if needed

2Based on comparison to the national average Annual Percentage Yield (APY) on savings accounts as published in the FDIC National Rates and Rate Caps, accurate as of September 15, 2025.

Common causes of sleeping with your mouth open include nasal congestion, allergies, and sleep apnea